DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2012/0259013 A1 Motwani Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2012/0259013 A1 Motwani Et Al US 201202590 13A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0259013 A1 Motwani et al. 43) Pub. Date: Oct. 11,9 2012 54) LIQUID DOSAGE FORMS OF ISOTRETINOIN 3O ForeignO Applicationication PriorityPriori D ata (75) Inventors: Sanjay Kumar Motwani, Bhopal May 20, 2009 (IN) ........................... 1039/DELA2009 (IN); Shashikanth P. Isloor, Publication Classification his (IN) Vinod Arora, (51) Int. Cl. urgaon (IN) A6II 3/19 (2006.01) A6IP 9/00 (2006.01) (73) Assignee: RANBAXY LABORATORIES A6IP 7/06 (2006.01) LIMITED, New Delhi, Delhi (IN) A6IP35/00 (2006.01) A6IP 700 (2006.01) A6IP 7/10 (2006.01) (21) Appl. No.: 13/320,164 A6IP 29/00 (2006.01) (52) U.S. Cl. ........................................................ 514/557 (22) PCT Filed: May 20, 2010 (57) ABSTRACT (86). PCT No.: PCT/B2O1O/O52254 The present invention relates to a pharmaceutical Solution comprising isotretinoin or salts thereof. The present invention S371 (c)(1), further relates to the processes for preparing Such composi (2), (4) Date: Jun. 25, 2012 tions. US 2012/02590 13 A1 Oct. 11, 2012 LIQUID DOSAGE FORMS OF ISOTRETINOIN forms like tablets or capsules. Thus an oral liquid is the preferred dosage form for pediatric patients. TECHNICAL FIELD OF THE INVENTION I0010 Apart from the alterations in the pharmacodynamics and pharmacokinetics, the geriatric population suffers from a 0001) The present invention relates to a pharmaceutical number of chronic conditions and physical limitations. Swal Solution comprising isotretinoin or a pharmaceutically lowing or chewing may be a problem for the elderly. For acceptable salt of isotretinoin and a process for the prepara example, patients suffering from dry mouth or who are eden tion thereof. tulous are incapable of chewing or Swallowing. This makes the liquid dosage form a popular choice with the elderly. BACKGROUND OF THE INVENTION I0011) A softgel capsule is the only dosage form available 0002) Isotretinoin is a retinoid, approved for the treatment for the oral administration of isotretinoin. However, the oral of severe recalcitrant nodular acne. Chemically, isotretinoin administration of solid forms such as tablets and capsules can is 13-cis-retinoic acid and is related to both retinoic acid and prove difficult or even dangerous for children and the elderly retinol (vitamin A). who prefer to take liquid dosage forms. Further, it has been 0003 Presently isotretinoin is marketed by Hoffman La reported that for administering isotretinoin to children or Roche under the brand name Accutane(R). This product com infants extemporaneous liquid formulations are made by prises a suspension of isotretinoin filled in soft gelatin cap piercing/cut-opening or squeezing the contents of the cap Sules. Sule. These extemporaneous preparations lead to an increased 0004 U.S. Pat. No. 4,322,438, assigned to Hoffman-La dosing variability and toxicity due to the metabolism of Roche, discloses a method of treating nodulocystic and con isotretinoin (13-cis retinoic acid) to tretinoin (all trans-ret globate acne in humans by oral administration of 13-cis inoic acid). Furthermore, the extemporaneous preparation retinoic acid in amounts and for periods of time which afford and dispensing of isotretinoin solution is not possible in a an effectively complete remission from the condition even typical hospital pharmacy set-up because of the poor solubil after administration of the compound ceases. ity, longer solubilization time, safety issues in handling a 0005 PCT Publication No. WO 00/25772, filed by Hoff teratogenic drug and photo-instability of the drug. man-La Roche, relates to soft gel capsules of isotretinoin (0012 Neuroblastoma is an embryonic malignancy of having improved bioavailability. This application discloses sympathetic nervous system and occurs almost exclusively in that the currently marketed AccutaneR) formulation of isotre infants and young children commonly aged between 1 and 5 tinoin has a mean particle size of 100 um and has a bioavail years. Currently, clinical trials are going forward to study the ability of only about 20%. Therefore, it discloses a process of effectiveness of isotretinoin in the treatment of neuroblas further reducing the particle size of isotretinoin to a range of toma in children. Treatment with isotretinoin is initiated dur about 5um to about 30 Jum, thereby improving the bioavail ing the maintenance phase. Alternate courses of isotretinoin ability of isotretinoin. and an anticancer drug are given. For example, Phase II 0006) European Patent No. EP 0 184942 B1, assigned to studies (sponsored by St. Jude Children's Research Hospital, Ortho Pharmaceutical Corporation discloses pharmaceutical NIH, AstraZeneca) on oral maintenance therapy with isotre compositions in the form of a soft gelatin capsule having no tinoin and topotecan, has been completed. These trials have more than a 22% wax content, as a critical limitation of the been conducted using isotretinoin soft gel capsules. During patent. Higher wax content tends to diminish the bioavailabil these trials children were either trained to swallow the capsule ity. or the contents from the capsule were squeezed into food 0007 U.S. Pat. No. 7,435,427, assigned to Galephar, dis causing increased dosing variability. Therefore, in the light of closes gelatin capsules comprising a semi solid suspension of prior art there is an unmet need of a stable oral liquid formu isotretinoin containing at least two lipidic excipients. lation of isotretinoin. 0008 Isotretinoin was initially developed and approved in 0013 Liquids are homogeneous preparations containing 1982 for the treatment of acne. There area number of ongoing one or more active ingredients dissolved or suspended in a Studies regarding the use of isotretinoin for treatment of mus Suitable vehicle or carrier. These include solutions, syrups, culoskeletal and connective tissue inflammations, emphy Suspensions, elixirs, or concentrates. Oral liquid dosage Sema, ulcerating diseases and various cancers, namely treat forms offer unique advantages over the solid dosage forms ing cervical tumors in HIV positive women, the prevention of like tablets and capsules. In addition to being more patient lung cancer in Smokers and the prevention of skin cancer. compliant, liquid dosage forms provide a more reproducible Studies have been recently completed or ongoing regarding bioavailability. These dosage forms provide rapid absorption the role of isotretinoin (usually in combination with other of drug from the GI tract. Additionally, liquid dosage forms drugs) in the treatment of neuroblastoma, recurrent prostrate allow the use of flavoring and/or palatability agents, which cancer, leukemia, high-grade glioma, head and neck cancers further promotes patient acceptance and compliance. Further, and multiple myeloma. Isotretinoin has also been proved to liquid formulations provide the option of a flexible dosing be useful in the treatment of certain dermatological condi regime based on body weight or body surface area. The most tions such as gram-negative folliculitis, recalcitrant rosacea, common liquid dosage forms include suspensions and solu pyoderma faciale, generalized lichen planus, psoriasis, cuta t1OnS. neous lupus erythematosus and acne fulminans, squamous (0014 Solutions offer several advantages over other liquid cell carcinoma. It is also used for the treatment of cutaneous dosage forms. These are absorbed faster and generally cause photoaging. less irritation of the gastrointestinal mucosa. Moreover, phase 0009. As is evident, many of these studies would target separation upon storage is not a concern with solutions. Com either pediatric or geriatric patients. Oral administration is the pared with suspensions, solutions are free from the gritty preferred route for children. However, children younger than feeling that particles in a suspension might cause. The other 5-6 years of age have a difficulty in Swallowing solid dosage advantages offered by the solution dosage form is that these US 2012/O2590 13 A1 Oct. 11, 2012 do not need to be shaken before use, the accuracy of the dose patient in a fed State, the Solution exhibits a maximum plasma is likely to be more than with the equivalent Suspension, no concentration (C) of isotretinoin comparable to that exhib particle growth is observed over time and it presents a homo ited under fasting state. geneous feel and taste. Another important advantage offered 0023. In another general aspect, the present invention also by solution is the reduction of lower inter-subject variability provides for a process of preparing a pharmaceutical Solution in pharmacokinetics, especially for highly variable molecules of isotretinoin. The process includes: (i) dissolving isotretin for e.g., isotretinoin. Further, a solution dosage form of isotre oin in a carrier by continuous stiffing at room temperature, or tinoin has not been available. at higher temperatures, till a homogenous solution is formed; 0015 Isotretinoin is a relatively water insoluble com and (ii) cooling the solution of step (i) to room temperature, pound and it degrades when exposed to light and atmospheric optionally, adding one or more excipients. oxygen. Further isotretinoin i.e., 13-cis retinoic acid, is a 0024. In another general aspect there is provided a process geometric isomer of tretinoin i.e., all-trans retinoic acid. of preparing a pharmaceutical Solution of isotretinoin. The These isomers show reversible interconversion. This inter process includes: (i) dissolving
Load more

Recommended publications
  • Analysis of the Most Appropriate Risk Management Option (Rmoa) ______
    ANALYSIS OF THE MOST APPROPRIATE RISK MANAGEMENT OPTION (RMOA) _________________________________________________________________ Analysis of the most appropriate risk management option (RMOA) Substance Name: 2,6-di-tert-butyl-p-cresol EC Number: 204-881-4 CAS Number: 128-37-0 Authority: France Date: March 2016 Cover Note 2,6-di-tert-butyl-p-cresol (butylated hydroxytoluene (BHT)) belongs to the broad group of alkyl phenols and as alkyl phenol ethoxylates BHT is on the Danish EPA “List of Undesirable Substances” latest updated in 2009. The group was recently reviewed in a report: “Survey of alkyl phenols and alkyl phenol ethoxylates (Danish EPA 2012). The group includes substances that are hazardous to the environment and substances that have or may have endocrine disrupting effects. The substance is also listed in the Danish inventory of carcinogenic substances. BHT is included in the framework on the French national Strategy on Endocrine Disruptors (Stratégie Nationale sur les Perturbateurs Endocriniens or SNPE) in 2015. ANSES was commissioned by the French Competent Authority (Ministry of Ecology, Sustainable Development and Energy) and identified BHT as a good candidate for working further on its ED properties. Consequently, France initiated a RMOA on BHT, mainly focused on the ED properties of this substance. EC no 204-881-4 Anses (on behalf FR-MSCA) Page 1 sur 48 ANALYSIS OF THE MOST APPROPRIATE RISK MANAGEMENT OPTION (RMOA) _________________________________________________________________ Indeed, alerts on BHT come from different sources. BHT shares common uses with BHA, that was analysed within the framework of SNPE in 2014 and which has been identified numerous times as a potential endocrine disruptors: European Commission on Endocrine Disruption (EDC Database): Listed BHA as a Category 1 priority substance, based on evidence that it interferes with hormone function.
    [Show full text]
  • Bht) (Casrn 128-37-0)
    EPA/690/R-13/003F l Final 6-05-2013 Provisional Peer-Reviewed Toxicity Values for Butylated Hydroxytoluene (BHT) (CASRN 128-37-0) Superfund Health Risk Technical Support Center National Center for Environmental Assessment Office of Research and Development U.S. Environmental Protection Agency Cincinnati, OH 45268 AUTHORS, CONTRIBUTORS, AND REVIEWERS CHEMICAL MANAGER J. Phillip Kaiser, PhD National Center for Environmental Assessment, Cincinnati, OH DRAFT DOCUMENT PREPARED BY ICF International 9300 Lee Highway Fairfax, VA 22031 PRIMARY INTERNAL REVIEWERS Ghazi Dannan, PhD National Center for Environmental Assessment, Washington, DC Q. Jay Zhao, PhD, MPH, DABT National Center for Environmental Assessment, Cincinnati, OH This document was externally peer reviewed under contract to Eastern Research Group, Inc. 110 Hartwell Avenue Lexington, MA 02421-3136 Questions regarding the contents of this document may be directed to the U.S. EPA Office of Research and Development’s National Center for Environmental Assessment, Superfund Health Risk Technical Support Center (513-569-7300). i TABLE OF CONTENTS COMMONLY USED ABBREVIATIONS ................................................................................... iii BACKGROUND .............................................................................................................................1 DISCLAIMERS ...............................................................................................................................1 QUESTIONS REGARDING PPRTVS ...........................................................................................1
    [Show full text]
  • Identification of in Vitro Metabolites of Synthetic Phenolic Antioxidants
    International Journal of Molecular Sciences Article Identification of In Vitro Metabolites of Synthetic Phenolic Antioxidants BHT, BHA, and TBHQ by LC-HRMS/MS Ons Ousji and Lekha Sleno * Chemistry Department, Université du Québec à Montréal, Downtown Station, P.O. Box 8888, Montréal, QC H3C 3P8, Canada; [email protected] * Correspondence: [email protected] Received: 30 October 2020; Accepted: 11 December 2020; Published: 15 December 2020 Abstract: Butylated hydroxytoluene (BHT) and its analogs, butylated hydroxyanisole (BHA) and tert-butyl-hydroquinone (TBHQ), are widely used synthetic preservatives to inhibit lipid oxidation in the food, cosmetic and pharmaceutical industries. Despite their widespread use, little is known about their human exposure and related biotransformation products. The metabolism of these compounds was investigated using in vitro incubations with human and rat liver fractions. Liquid chromatography coupled to high-resolution tandem mass spectrometry was employed to detect and characterize stable and reactive species formed via oxidative metabolism, as well as phase II conjugates. Several oxidative metabolites have been detected, as well as glutathione, glucuronide, and sulfate conjugates, many of which were not previously reported. A combination of accurate mass measurements, MS/MS fragmentation behavior, and isotope-labeling studies were used to elucidate metabolite structures. Keywords: BHT; BHA; synthetic antioxidant; metabolites; in vitro incubations; liquid chromatography; high-resolution tandem mass spectrometry 1. Introduction Synthetic phenolic antioxidants were developed in the late 1940s [1]. They have been used in food, pharmaceuticals, cosmetic, and petrochemical industries to increase shelf life and to improve the quality, freshness, taste, and texture of consumer products [2]. They are widely used to trap free radicals and delay lipid oxidation in various products [1].
    [Show full text]
  • Micellization, Interaction and Thermodynamic Study of Butylated
    Journal of Saudi Chemical Society (2012) xxx, xxx–xxx King Saud University Journal of Saudi Chemical Society www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Micellization, interaction and thermodynamic study of butylated hydroxyanisole (synthetic antioxidant) and sodium dodecyl sulfate in aqueous-ethanol solution at 25, 30 and 35 °C Varun Bhardwaj a, Poonam Sharma a,*, M.S. Chauhan b, S. Chauhan b a Department of Biotechnology, Bioinformatics and Pharmacy, Jaypee University of Information Technology, Waknaghat, Solan, 173234 Himachal Pradesh, India b Department of Chemistry, Himachal Pradesh University, Summer Hill, Shimla, 171005 Himachal Pradesh, India Received 28 May 2012; accepted 14 September 2012 KEYWORDS Abstract Surfactants are found to enhance the diffusion significantly depending on hydrophobic/ Critical micelle concentra- hydrophilic group lengths and the structure of the surfactant molecule. Aggregation properties of tion; sodium dodecyl sulfate (SDS) in the presence of butylated hydroxyanisole (synthetic antioxidant), SDS; at a range of temperatures (25, 30 and 35 °C) have been measured by the conductometric study in Butylated hydroxyanisole aqueous-ethanolic composite solution. The experimental data of aqueous-ethanolic solutions as a (synthetic-antioxidant); function of SDS concentration ranging from 1 to 14 mM dmÀ3 show the presence of inflexion Interaction points indicating micellization and interaction mechanisms. Effect of temperature was also observed in increasing the CMC (Critical Micelle Concentration) in the narrow composition. From the CMC values as a function of temperature, various thermodynamic parameters have been evaluated viz: (a) the standard enthalpy change (DHm), (b) standard entropy change (DSm), and (c) standard Gibbs energy change (DGm). The results showed that the presence of alcohol, as well as the compo- sition of water + ethanol may have effect on thermodynamic parameters.
    [Show full text]
  • Butylated Hydroxytoluene (BHT) Crops
    Butylated Hydroxytoluene (BHT) Crops 1 2 Executive Summary 3 A petition was filed with the NOSB to use butylated hydroxytoluene (BHT) as an antioxidant in a number of pheromone 4 formulations. Pheromones and BHT would be enclosed in a plastic matrix, allowing slow release of the materials into the 5 air. Due to low volatility of BHT, most of it would remain in the dispenser and direct contact with the crop would be 6 negligible. BHT is an alkylated cresol that can be synthesized several ways. The p-cresol starting material is isolated from 7 coal tar or petroleum. It is also obtained synthetically from toluene. The p-cresol is alkylated with isobutylene gas in the 8 presence of an acidic catalyst to produce BHT. It is used as an antioxidant in food, and is also used as a stabilizer in 9 pesticides, gasoline, lubricants, soaps and cosmetics, and as an antiskinning agent in paints and inks. 10 11 The material has not been reviewed by NOSB before, and because it is synthetic and on List 3, is currently prohibited for 12 use in organic production under the National Organic Program Standards. However, pheromone formulations that use 13 BHT have been widely used by organic farmers. Impacts on the environment and human health from this application 14 should be negligible. The TAP reviewers unanimously concluded that BHT should be added to the National List as an 15 allowed synthetic with the annotation: for use in organic crop production systems as an antioxidant for pheromones 16 enclosed in plastic dispensers. The reviewers were all concerned with the precedent that this set, and made it clear that 17 addition to the National List should be made only if application and use is limited.
    [Show full text]
  • Butylated Hydroxyanisole Troleum Products (IARC 1986)
    Report on Carcinogens, Fourteenth Edition For Table of Contents, see home page: http://ntp.niehs.nih.gov/go/roc Butylated Hydroxyanisole troleum products (IARC 1986). Food-grade BHA contains over 85% 3-BHA and less than 15% 2-BHA, while cosmetic-grade BHA con- CAS No. 25013-16-5 tains 90% 3-BHA and 8% 2-BHA. Since 1947, BHA has been added to edible fats and fat-containing foods for its antioxidant properties. Reasonably anticipated to be a human carcinogen It is also used in foods cooked or fried in animal oils, because of its First listed in the Sixth Annual Report on Carcinogens (1991) high thermal stability and its ability to remain active in baked and Also known as BHA or or (1,1-dimethylethyl)-4-methoxyphenol fried foods (HSDB 2009). BHA is added to butter, lard, meats, cereals, baked goods, sweets, beer, vegetable oils, potato chips, snack foods, H3C H3C nuts and nut products, dehydrated potatoes, and flavoring agents. It O CH3 O is used in sausage, poultry and meat products, dry mixes for bever- CH3 C ages and desserts, glazed fruits, chewing gum, active dry yeast, de- CH3 foaming agents for beet sugar and yeast, and emulsion stabilizers for CH3 C shortening (IARC 1986). BHA stabilizes the petroleum wax coatings CH3 of food packaging (HSDB 2009). BHA is considered by the U.S. Food OH CH OH 3 and Drug Administration (FDA) to be generally recognized as safe 2-BHA 3-BHA when the antioxidant content does not exceed 0.02% by weight of the Carcinogenicity food’s total fat or oil content.
    [Show full text]
  • Draft Screening Assessment
    Screening Asse ssment for the Challenge Phenol, (1,1-dimethylethyl)-4-methoxy- (Butylated hydroxyanisole) Chemical Abstracts Service Registry Number 25013-16-5 Environment Canada Health Canada July 2010 Screening Assessment CAS RN 25013-16-5 Synopsis The Ministers of the Environment and of Health have conducted a screening assessment of phenol, (1,1-dimethylethyl)-4-methoxy- (also known as butylated hydroxyanisole or BHA), Chemical Abstracts Service Registry Number 25013-16-5. The substance BHA was identified in the categorization of the Domestic Substances List as a high priority for action under the Challenge, as it was determined to present intermediate potential for exposure of individuals in Canada and was considered to present a high hazard to human health, based upon classification by other agencies on the basis of carcinogenicity. The substance did not meet the ecological categorization criteria for persistence, bioaccumulation or inherent toxicity to aquatic organisms. Therefore, this assessment focuses principally upon information relevant to the evaluation of risks to human health. According to information reported in response to a notice published under section 71 of the Canadian Environmental Protection Act, 1999 (CEPA 1999), no BHA was manufactured in Canada in 2006 at quantities equal to or greater than the reporting threshold of 100 kg. However, between 100 and 1000 kg of BHA was imported into Canada, while between 1000 and 10 000 kg of BHA was used in Canada alone, in a product, in a mixture or in a manufactured item. BHA is permitted for use in Canada as an antioxidant in food. In fats and fat-containing foods, BHA delays the deterioration of flavours and odours and substantially increases the shelf life.
    [Show full text]
  • Synthetic Phenolic Antioxidants, Including Butylated Hydroxytoluene (BHT), in Resin-Based Dental Sealants
    Environmental Research 151 (2016) 339–343 Contents lists available at ScienceDirect Environmental Research journal homepage: www.elsevier.com/locate/envres Synthetic phenolic antioxidants, including butylated hydroxytoluene (BHT), in resin-based dental sealants Wei Wang a, Pranav Kannan a, Jingchuan Xue a, Kurunthachalam Kannan a,b,n a Wadsworth Center, New York State Department of Health, and Department of Environmental Health Sciences, School of Public Health, State University of New York at Albany, Empire State Plaza, P.O. Box 509, Albany, NY 12201-0509, United States b Biochemistry Department, Faculty of Science, Experimental Biochemistry Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia article info abstract Article history: Resin-based dental sealants (also referred to as pit-and-fissure sealants) have been studied for their Received 28 June 2016 contribution to bisphenol A (BPA) exposure in children. Nevertheless, little attention has been paid to the Received in revised form occurrence of other potentially toxic chemicals in dental sealants. In this study, the occurrence of six 29 July 2016 synthetic phenolic antioxidants (SPAs), including 2,6-di-tert-butyl-4-hydroxytoluene (BHT), 2,6-di-tert- Accepted 30 July 2016 butyl-4-(hydroxyethyl)phenol (BHT-OH), 3,5-di-tert-butyl-4-hydroxy-benzaldehyde (BHT-CHO), 2,6-di- tert-butylcyclohexa-2,5-diene-1,4-dione (BHT-Q), 3,5-di-tert-butyl-4-hydroxybenzoic acid (BHT-COOH) Keywords: and 2-tert-butyl-4-methoxyphenol (BHA), was examined in 63 dental sealant products purchased from Dental sealant the U.S. market. BHT was found in all dental sealants at median and maximum concentrations of 56.8 and Synthetic phenolic antioxidant 1020 mg/g, respectively.
    [Show full text]
  • A Review of the Physiological Implications of Antioxidants in Food
    A Review of the Physiological Implications of Antioxidants in Food Interactive Qualifying Project Report Submitted to the Faculty of the WORCESTER POLYTECHNIC INSTITUTE in partial fulfillment of the requirements for the Degree of Bachelor of Science By _________________________________ _________________________________ Rashmi Venkatesh Disha Sood Date: January 14, 2011 Approved: _________________________________ Satya Shivkumar 1 Abstract Antioxidants have been known to prevent oxidation reactions, inhibiting conditions such as cancer and heart disease. The purpose of this IQP is to explore natural and synthetic antioxidants used as preservatives. It was found that both the concentration and the absorption mechanism of natural antioxidants are important in obtaining the maximum beneficial effect. Additionally, synthetic antioxidants used as preservatives have shown evidence of toxicity in animal models, though more research needs to be done to fully understand their physiological effects. 2 Acknowledgements Foremost, we would like to thank Professor S. Shivkumar for advising this project. He has given us many valuable hours of his time in order for this project to become a reality. Without him, this paper would not have been a possibility and we are very grateful for his indispensable time, effort, and guidance. We would also like to thank Professor J. Skorinko for her help in performing the statistical analysis of our survey results. Without her help, we would not have been able to efficiently analyze or raw data. Additionally, we would like to thank Professor D. Heilman of the Worcester Polytechnic Institute Dept. of Chemistry and Biochemistry for his additional help, guidance and encouragement during the course of writing this paper. Finally, we would like to thank our friends and families, who helped us disseminate the survey, and all those who supported us during these months of hard work.
    [Show full text]
  • Antioxidant Activity of Methanolic Extracts from Three Coriander (Coriandrum Sativum L.) Fruit Varieties
    Arabian Journal of Chemistry (2014) xxx, xxx–xxx King Saud University Arabian Journal of Chemistry www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Antioxidant activity of methanolic extracts from three coriander (Coriandrum sativum L.) fruit varieties Kamel Msaada *, Mariem Ben Jemia, Nidhal Salem, Olfa Bachrouch, Jazia Sriti, Sonia Tammar, Iness Bettaieb, Iness Jabri, Sara Kefi, Ferid Limam, Brahim Marzouk Laboratory of Bioactive Substances, Biotechnology Center in Borj-Cedria Technopol, BP. 901, 2050 Hammam-Lif, Tunisia Received 14 August 2012; accepted 16 December 2013 KEYWORDS Abstract In this study, fruit methanolic extract of three coriander (Coriandrum sativum L.) varie- Coriandrum sativum L.; ties (Tunisian, Syrian and Egyptian) was assayed for their antioxidant activities. Obtained results Fruit; showed that there are significant (P < 0.05) variations in total polyphenols (0.94 ± 0.05– Methanolic extract; 1.09 ± 0.02 mg GAE/g DW), total flavonoids (2.03 ± 0.04–2.51 ± 0.08 mg EC/g DW) and total Polyphenols; condensed tannin (0.09 ± 0.01–0.17 ± 0.01 mg EC/g DW) contents. The RP-HPLC analysis Antioxidant activities revealed the identification of phenolics in coriander fruits with chlorogenic and gallic acids as main compounds in Tunisian, Syrian and Egyptian varieties, respectively. Moreover, fruit methanolic extracts exhibited remarkable DPPH radical scavenging activity with IC50 values ranged from 27.00 ± 6.57 to 36.00 ± 3.22 lg/mL. EC50 values of reducing power activity varied significantly (P < 0.05) from 54.20 ± 6.22 to 122.01 ± 13.25 lg/mL. The IC50 values of b-carotene bleaching assay were between 160.00 ± 18.63 and 240.00 ± 26.35 lg/mL.
    [Show full text]
  • Butylated Hydroxyanisole, Butylated Hydroxytoluene
    Toxicology Reports 5 (2018) 31–37 Contents lists available at ScienceDirect Toxicology Reports journal homepage: www.elsevier.com/locate/toxrep Hepatoprotective effect of food preservatives (butylated hydroxyanisole, T butylated hydroxytoluene) on carbon tetrachloride-induced hepatotoxicity in rat ⁎ ⁎ Barsha Dassarmaa, , Dilip K. Nandib, Somnath Gangopadhyayc, Saptadip Samantaa, a Department of Physiology, Midnapore College, Midnapore, 721101, West Bengal, India b Department of Physiology and Nutrition, Raja N.L. Khan Women’s College, Midnapore, 721102, West Bengal, India c Department of Physiology, Occupational Ergonomics Laboratory, University College of Science and Technology, University of Calcutta, 92 APC Road, Calcutta, 700009, West Bengal, India ARTICLE INFO ABSTRACT Keywords: Carbon tetrachloride (CCl4), a hepatotoxic agent is widely used to study the toxic mechanisms in experimental Butylated hydroxyanisole animals. This study was carried out to establish the hepatoprotective measures of food preservative antioxidants Butylated hydroxytoluene butylated hydroxyanisole and butylated hydroxytolune (BHA, BHT) when mixed with food towards carbon Hepatoprotection tetrachloride (CCl4) intoxication (230 mg/ kg b wt/rat/day) in rat. Biochemical markers like serum glutamate CCl - intoxicated rats 4 pyruvate tranaminase (AST), serum glutamate oxaloacetate transaminase (ALT), alkaline phosphatase (ALP) and bilirubin content, antioxidant enzymes such as SOD, CAT, GPx, and malondialdehyde (MDA) as the end product of lipid peroxidanion were measured. The results had shown the elevated level of AST (121.16%), ALT (124.68%), ALP (122.41%) an, bilirubin content (57.14%) after CCl4 treatment. Marked decrease of activity of antioxidant enzymes such as SOD (85.36%), CAT (67.47%), GPx (50.7%) had indicated that the ROS mediated toxicity and pretreatment of BHA and BHT restored the activity of these enzymes.
    [Show full text]
  • Butylated Hydroxytoluene B
    Butylated Hydroxytoluene B 1 Nonproprietary Names Table I: Antioxidant uses of butylated hydroxytoluene. BP: Butylated Hydroxytoluene Antioxidant use Concentration (%) PhEur: Butylhydroxytoluene b USP-NF: Butylated Hydroxytoluene -Carotene 0.01 Edible vegetable oils 0.01 Essential oils and flavoring agents 0.02–0.5 Fats and oils 0.02 2 Synonyms Fish oils 0.01–0.1 Inhalations 0.01 Agidol; BHT; 2,6-bis(1,1-dimethylethyl)-4-methylphenol; butyl- IM injections 0.03 hydroxytoluene; butylhydroxytoluenum; Dalpac; dibutylated IV injections 0.0009–0.002 hydroxytoluene; 2,6-di-tert-butyl-p-cresol; 3,5-di-tert-butyl-4- Topical formulations 0.0075–0.1 hydroxytoluene; E321; Embanox BHT; Impruvol; Ionol CP; Vitamin A 10 mg per million units Nipanox BHT; OHS28890; Sustane; Tenox BHT; Topanol; Vianol. 9 Pharmacopeial Specifications 3 Chemical Name and CAS Registry Number See Table II. 2,6-Di-tert-butyl-4-methylphenol [128-37-0] Table II: Pharmacopeial specifications for butylated hydroxytoluene. 4 Empirical Formula and Molecular Weight Test PhEur 6.0 USP32–NF27 Identification þþ C15H24O 220.35 Characters þ — Appearance of solution þ — Congealing temperature — 569.28C 5 Structural Formula Freezing point 69–708C— Residue on ignition — 40.002% Sulfated ash 40.1% — Heavy metals — 40.001% Related substances þþ Assay — 599.0% 10 Typical Properties Boiling point 2658C Density (bulk) 0.48–0.60 g/cm3 Density (true) 1.031 g/cm3 Flash point 1278C (open cup) Melting point 708C Moisture content 40.05% NIR spectra see Figure 1. 6 Functional Category Partition coefficient Octanol : water = 4.17–5.80 75 Antioxidant. Refractive index n D = 1.4859 Solubility Practically insoluble in water, glycerin, propylene glycol, solutions of alkali hydroxides, and dilute aqueous mineral acids.
    [Show full text]